Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 3/20 | 0.82 |
| ▸ | MC5R | P33032 | 2/20 | 0.82 |
| ▸ | MC3R | P41968 | 2/20 | 0.82 |
| ▸ | MC1R | Q01726 | 2/20 | 0.82 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.70 |
| ▸ | CTSL | P07711 | 3/20 | 0.69 |
| ▸ | CTSS | P25774 | 3/20 | 0.69 |
| ▸ | CTSK | P43235 | 3/20 | 0.69 |
| ▸ | CTSH | P09668 | 1/20 | 0.69 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.64 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.63 |
| ▸ | GLP1R | P43220 | 4/20 | 0.63 |
| ▸ | GCGR | P47871 | 3/20 | 0.60 |
| ▸ | NMBR | P28336 | 1/20 | 0.60 |
| ▸ | GRPR | P30550 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Intermedine SCHEMBL20548027 | 1.00 | MC4R (0.82) | MC4RMC5RMC3RMC1RC5AR1 | |
| Intermedine SCHEMBL22076809 | 1.00 | MC4R (0.82) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29534172 | 0.98 | MC4R (0.78) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29430238 | 0.96 | MC4R (0.78) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29533733 | 0.96 | MC4R (0.78) | MC4RMC5RMC3RMC1RC5AR1 | |
| Afamelanotide SCHEMBL29419548 | 0.96 | MC4R (0.81) | MC4RMC5RMC3RMC1RC5AR1 | |
| Afamelanotide SCHEMBL22463810 | 0.96 | MC4R (0.81) | MC4RMC5RMC3RMC1RC5AR1 | |
| Afamelanotide SCHEMBL29352792 | 0.96 | MC4R (0.81) | MC4RMC5RMC3RMC1RC5AR1 | |
| Afamelanotide SCHEMBL22463811 | 0.96 | MC4R (0.81) | MC4RMC5RMC3RMC1RC5AR1 | |
| Afamelanotide SCHEMBL29533175 | 0.95 | MC4R (0.80) | MC4RMC5RMC3RMC1RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117235175-A | Ship product data cross-unit sharing method based on SCIM and IPDE | 中国舰船研究设计中心 | 2023-12-15 | — | — | CN | claimed |
| CN-122020886-A | Method, system, equipment and storage medium for designing residual stress of wheel disc | 中国航发湖南动力机械研究所 | 2026-05-12 | — | — | CN | disclosed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062460-A1 | METHODS FOR TREATING ACUTE CORONARY SYNDROME USING APOA-1 FUSION PROTEINS | THERIPION, INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260062709-A1 | METHODS FOR IMPROVING PRODUCTION OF BIOLOGICAL PRODUCTS BY REDUCING THE LEVEL OF ENDOGENOUS PROTEIN | LONZA AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-12534511-B2 | Serum albumin-binding fibronectin type III domains | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-27 | — | — | US | disclosed |
| US-12529088-B2 | Helper factors for expressing proteins in yeast | LONZA LTD (CH) | 2026-01-20 | — | — | US | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| US-20220049275-A1 | SSI CELLS WITH PREDICTABLE AND STABLE TRANSGENE EXPRESSION AND METHODS OF FORMATION | LONZA AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-20220042064-A1 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | LONZA LTD (CH) | 2022-02-10 | — | — | US | disclosed |
| EP-3947695-A1 | MUT- METHYLOTROPHIC YEAST | Universität für Bodenkultur Wien (AT) | 2022-02-09 | — | — | EP | disclosed |
| CN-114026239-A | MUT-methanol nutritional yeast | 维也纳自然资源与生命科学大学 | 2022-02-08 | — | — | CN | disclosed |
| CN-114026213-A | Continuous blade type impeller | 龙沙有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11236520-B2 | Customizable facility | LONZA LTD (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-3942014-A1 | CONTINUOUS BLADE IMPELLER | Lonza Ltd. (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062460-A1 | METHODS FOR TREATING ACUTE CORONARY SYNDROME USING APOA-1 FUSION PROTEINS | PON1, APOB, APOL1 | MC4R 4626/4885MC5R 4761/4885MC3R 4639/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | MC4R 616/4885MC5R 2160/4885MC3R 750/4885 |
| US-12534511-B2 | Serum albumin-binding fibronectin type III domains | FN1, ALB, FGB | MC4R 4106/4885MC5R 4148/4885MC3R 2261/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | MC4R 455/4885MC5R 1631/4885MC3R 1112/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | MC4R 1730/4885MC5R 1072/4885MC3R 1639/4885 |
| US-20260062709-A1 | METHODS FOR IMPROVING PRODUCTION OF BIOLOGICAL PRODUCTS BY REDUCING THE LEVEL OF ENDOGENOUS PROTEIN | MRPL21, SET, RPS27A | MC4R 4184/4885MC5R 4115/4885MC3R 4142/4885 |
| US-12529088-B2 | Helper factors for expressing proteins in yeast | UPF1, ILF3, YIF1A | MC4R 4874/4885MC5R 4877/4885MC3R 4876/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | MC4R 222/4885MC5R 409/4885MC3R 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.